AstraZeneca D9722C00001 EvoPAR

A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

AstraZeneca Tropion-Breast02            

A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02)

AstraZeneca Tropion-Breast03

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-IIITriple-negative Breast Cancer who have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)

BioNTech BNT327-02

A Phase II, multi-site, randomized, open-label clinical trial to evaluate the safety, efficacy, and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer

Celcuity  CELC-G-301  

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy.

Duality DB-1303-O-3002 Dynasty Breast02

A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) 

(DYNASTY-Breast02)

Genentech WO43571

A Phase III, Randomized, Open-Label Studyevaluating The Efficacy And Safety Ofgiredestrant In Combination With Phesgoversus Phesgo After Induction Therapy Withphesgo+ Taxane In Patients With Previously untreated Her2-Positive, Estrogen Receptor positive Locally-Advanced Or Metastatic Breast Cancer

Gilead GS-US-595-6184                            

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.

Daiichi Sankyo DS7300-188

A phase 3, multicenter, randomized, Open-label study of Ifinatamab Deruxtecan (i-dxd), a b7-h3 antibody drug conjugate (adc), versus treatment of physician’s Choice (tpc) in subjects with relapsed Small Cell Lung Cancer (sclc) (Ideate-lung02)

BioNTech BNT327-01

A Phase II, multi-site, open-label, parallel group trial of BNT327 in combination with chemotherapy for participants with untreated extensive-stage small-cell lung cancer and participants with previously treated small-cell lung cancer 

AstraZeneca D419ML00003

A Phase lllb, Randomized, Multicenter, Open-label study, to assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small-Cell Lung Cancer Patients who have Mutations or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

AstraZeneca D7680C00001 LOOP

An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

AstraZeneca AZD798AC00001 eVOLVE

A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02)

OSE 2101C302 ARTEMIA

A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI)- ARTEMIA study (Pro00076856)

Revolution Medicines RMC-LUNG-101

Subprotocol A - A Phase 1b/2 Open-Label, Multicenter Study of RMC-6291 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with KRASG12C-Mutated Solid Tumors.

Subprotocol B - A Phase 1b/2 Open-Label, Multicenter Study of RMC-6236 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC).

Regeneron R3767-ONC-2235

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-Lag-3 Antibody) in Combination with Cemiplimab (Anti-Pd-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment Of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 >/= 50%.

Regeneron R3767-ONC-2236

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-Lag-3 Antibody), Cemiplimab (Anti-Pd-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy In First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer (Nsclc) Irrespective Of Pd-L1 Expression Levels.

Eli Lilly J3M-MC-JZQB SUNRAY-01

A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression.

​

Janssen Cocoon 61186372NSC2007

A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + Lazertinib

CG Pharmaceuticals CG-745-2-08

A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy.

Daiichi Sankyo DS7300-203
A phase 2 pan-tumor, open-label study to evaluate the efficacy and safety of
Ifinatamab deruxtecan (i-dxd) in subjects with recurrent or metastatic Solid Tumors.
Non-Squamous NSCLC permanently closed
HCC and PDAC temporarily closed pending amendment changes

Daiichi Sankyo DS3201-324
A phase 1b, multicenter, open-label study of Valemetostat Tosylate in combination with dxd adcs in subjects with Solid Tumors (study of Valemetostat in combination With dxd adcs)